Abstract
Background Heated tobacco products (HTPs) are widespread in Japan, and smoking cessation of such products have become an important issue owing to the dissemination of the harmful effects of HTPs. The efficacy of online digital therapy has been reported in smoking cessation treatment; however, we have limited evidence of online smoking cessation program for HTP users. In this study, we evaluate the usefulness of the “ascure” program for people using HTPs (exclusive HTP use or dual use of HTP and cigarettes) compared with exclusive cigarette users.
Methods This was a retrospective study. We recruited adult smokers participating in the ascure online smoking cessation program in Japan from June 2019 to February 2021. The primary outcome was the chemically validated continuous abstinence rate (CAR) at weeks 21–24 using salivary cotinine testing. We also assessed CAR 9–12 and program adherence.
Findings We analyzed data from 2952 participants (52% for cigarette group, 35% for HTP group, and 13% for dual-use group), the mean age was 43·4 ± 10·8 years, 17% were women. Exclusive HTP user were more likely to stop tobacco use than exclusive cigarette smokers in CAR 21–24 (52.6% for cigarettes vs. 64.8% for HTP; OR: 1·17; 95% CI: 1·12–1·22; p < .001).
Interpretation Exclusive HTP users had higher CARs and adherence compared with exclusive cigarette users, indicating a higher affinity for the ascure online smoking cessation program. This program might be a useful smoking cessation option for HTP users as well as cigarette smokers.
Funding CureApp, Inc.
Evidence before this study Heated tobacco products have been widespread in Japan recently, and smoking cessation of these tobacco products became an important issue due to the gradual revealing of HTPs’ harmful effects on health.
Besides, the efficacy of new online digital therapy has been reported in smoking cessation treatment.
We searched PubMed on Dec 14, 2021, for publications on the effects of Heated tobacco on health and its relation to smoking cessation, using the terms “Heated tobacco products”, “smoking cessation” and “ digital therapy “ with no restrictions on publication date. We excluded studies that reported specifically on electronic cigarettes.
We found evidence about the harmful effect on the health of using HTPs, and the status and issues of smoking cessation, a moreover new attempt at smoking cessation using digital therapy.
However, the efficacy of smoking cessation treatment was mostly limited to conventional cigarettes especially digital therapy we found little evidence regarding smoking cessation by tobacco products such as HTPs.
Added value of this study In this study, we evaluated the usefulness of the ascure online smoking cessation program by tobacco products with a chemically validated index.
The continuous abstinence rates (CARs) 21-24 was higher in the exclusive HTP group than the exclusive cigarettes group. Moreover, there was no significant difference between the exclusive cigarettes and the dual-use groups.
Implications of all the available evidence The number of HTP users is currently increasing in Japan. In addition, online medical treatment is becoming more widespread and is expected to solve medical issues.
The results of this study indicating a higher affinity for the ascure online smoking cessation program. This program might be a useful smoking cessation option for HTP users.
Competing Interest Statement
AN and TT was supported by a KAKEN Grant-in-Aid for Scientific Research (A) (21H04856). AN also received consulting fees from CureApp, Inc., Japan. YN, RS, and MS are employees of CureApp, Inc., Japan.
Funding Statement
This study was funded by CureApp, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board of Kanazawa University, Japan (no. 2021-184 [113839]).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this study have been prepared under ethical considerations for specific research purposes and are not available to the public.
